{"url_path":"/sec/aimdw/8-k/2026-01-05/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-01-05","source_url":"https://www.sec.gov/Archives/edgar/data/1014763/0001493152-26-000271-index.html","accession_number":"0001493152-26-000271","cik":"0001014763","ticker":"AIMD","issuer_name":"Ainos, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1014763/0001493152-26-000271-index.html","primary_entity_key":"0001014763","primary_entity_name":"Ainos, Inc."},"word_count":740,"has_tables":true,"body_markdown":"** **\n\n**Item\n7.01 Regulation FD Disclosure**\n\n \n\nOn\nJanuary 5, 2026, Ainos, Inc. (the “Company”) announced its long-term platform strategy to digitize smell and establish scent\nas a native data language for artificial intelligence. The Company is executing a disciplined, layered SmellTech platform architecture\ndesigned to support scalability, data integrity, and long-term value creation.\n\n \n\nUnder\nthis architecture, the Company operates at the edge of the physical world, designing, manufacturing, and deploying its proprietary AI\nNose sensing hardware, while maintaining control over sensor design, firmware, calibration, manufacturing processes, quality assurance,\nand global certifications. This approach enables the generation of reliable and repeatable scent data suitable for large-scale AI training.\n\n \n\nThe\nCompany’s wholly owned AI software subsidiary, ScentAI Inc. (“ScentAI”), operates as the intelligence layer of the\nplatform, focusing on AI model development, data abstraction, and intelligence delivery. ScentAI does not design or sell hardware. The\nCompany believes this structural separation preserves platform clarity, governance consistency, and long-term scalability.\n\n \n\nScentAI\nis developing the Smell Language Model (SLM), a core AI system designed to classify, contextualize, and enable cross-environment learning\nof scent data in a structured, trainable format. As hardware deployments expand, the volume and diversity of scent data are expected\nto increase, supporting continued AI model improvement and the development of recurring, intelligence-driven software services over time.\n\n \n\nIn\n2026, the Company plans to transition from validation to scaled deployment, with an initial focus on advanced semiconductor manufacturing\nand robotic applications. These environments are intended to support accelerated data accumulation and AI model training and are not\nintended to define the ultimate scope of the Company’s addressable markets.\n\n \n\nThe\ninformation furnished with this Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of\nSection 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities\nof that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended,\nor the Exchange Act.\n\n \n\n**Forward-Looking\nStatements**\n\n** **\n\nThis\nCurrent Report on Form 8-K and certain of the materials filed herewith contain forward-looking statements within the meaning of Section\n27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other\nthan statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current\nassumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations\nor financial performance, and actual results and other events may differ materially from those expressed or implied in such statements\ndue to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which\ncannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions\nor other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include,\namong other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability\nto raise additional capital to continue our product development; our ability to accurately predict our future operating results; our\nability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize\nany product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing\nthe development and commercialization of our current and future product candidates; developing and commercializing additional products,\nincluding diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs,\nand factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking\nstatements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions\nof future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required\nby applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information,\nfuture events and developments or otherwise.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**Ainos,\nInc.**\n\n \n \n\nDate:\nJanuary 5, 2026\nBy:\n*/s/\nChun-Hsien Tsai*\n\n \nName:\nChun-Hsien\nTsai\n\n \nTitle:\nChief\nExecutive Officer"}